Tumor vascular changes mediated by inhibition of oncogenic signaling

Cancer Research

Volumn 69, Issue 15, 2009, Pages 6347-6354

  Qayum, Naseer ^a   Muschel, Ruth J ^a   Jae, Hong Im ^a   Balathasan, Lukxmi ^a   Koch, Cameron J ^b   Patel, Sonal ^c   Gillies McKenna, W ^a   Bernhard, Eric J ^a,d  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c Piramed Pharma   (United Kingdom)

^d CHURCHILL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2 (4 HYDROXYPHENYL) 4 MORPHOLINOPYRIDO[3',2':4,5]FURO[3,2 D]PYRIMIDINE; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; GEFITINIB; L 778123; NELFINAVIR; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PROTEIN KINASE B INHIBITOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER INHIBITION; CANCER THERAPY; CARCINOGENESIS; CONTROLLED STUDY; DRUG MECHANISM; HUMAN; HUMAN CELL; HYPOXIA; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR BLOOD FLOW; TUMOR VASCULARIZATION; TUMOR XENOGRAFT;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANIMALS; CELL HYPOXIA; CELL LINE, TUMOR; ENZYME INHIBITORS; FEMALE; FIBROSARCOMA; HUMANS; MICE; MICE, SCID; MICE, TRANSGENIC; NEOVASCULARIZATION, PATHOLOGIC; OXYGEN; PROTO-ONCOGENE PROTEINS C-AKT; RAS PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 68049144956     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-09-0657     Document Type: Article

References (40)

1. Baluk P , Morikawa S, Haskell A, Mancuso M, McDonald DM. Abnormalities of basement membrane on blood vessels and endothelial sprouts in tumors. Am J Pathol 2003;163:1801-1815 (Pubitemid 37310012)
2. Morikawa S, Baluk P, Kaidoh T, Haskell A, Jain RK, McDonald DM. Abnormalities in pericytes on blood vessels and endothelial sprouts in tumors. Am J Pathol 2002;160:985-1000. (Pubitemid 34224587)
3. Boucher Y, Baxter LT, Jain RK. Interstitial pressure gradients in tissue-isolated and subcutaneous tumors: implications for therapy. Cancer Res 1990;50:4478-4484 (Pubitemid 20230379)
4. Vaupel P. Tumor microenvironmental physiology and its implications for radiation oncology. Semin Radiat Oncol 2004;14:198-206. (Pubitemid 38903223)
5. Cosse JP, Michiels C. Tumour hypoxia affects the responsiveness of cancer cells to chemotherapy and promotes cancer progression. Curr Med Chem Anti-Canc Agents 2008;8:790-797
6. Teicher BA. Hypoxia and drug resistance. Cancer Metastasis Rev 1994;13:139-168
7. Horsman MR, Ehrnrooth E, Ladekarl M, Overgaard J. The effect of combretastatin A-4 disodium phosphate in a C3H mouse mammary carcinoma and a variety of murine spontaneous tumors. Int J Radiat Oncol Biol Phys 1998;42:895-898 (Pubitemid 28559438)
8. Chaplin DJ, Hill SA. The development of combretastatin A4 phosphate as a vascular targeting agent. Int J Radiat Oncol Biol Phys 2002;54:1491-1496 (Pubitemid 35380054)
9. Rak J, Filmus J, Finkenzeller G, Grugel S, Marme D, Kerbel RS. Oncogenes as inducers of tumor angiogenesis. Cancer Metastasis Rev 1995;14:263-277
10. Jain RK. Normalizing tumor vasculature with antiangiogenic therapy: a new paradigm for combination therapy [see comment]. Nat Med 2001;7:987-989
11. Cohen-Jonathan E, Evans SM, Koch CJ, et al. The farnesyltransferase inhibitor L744,832 reduces hypoxia in tumors expressing activated H-ras. Cancer Res 2001;61:2289-2293 (Pubitemid 32692061)
12. Pore N, Gupta AK, Cerniglia GJ, et al. Nelfinavir down-regulates hypoxia-inducible factor 1a and VEGF expression and increases tumor oxygenation: implications for radiotherapy. Cancer Res 2006;66:9252-9259 (Pubitemid 44521147)
13. Jugold M, Palmowski M, Huppert J, et al. Volumetric high-frequency Doppler ultrasound enables the assessment of early antiangiogenic therapy effects on tumor xenografts in nude mice. Eur Radiol 2008;18:753-758
14. Wei K, Jayaweera AR, Firoozan S, Linka A, Skyba DM, Kaul S. Quantification of myocardial blood flow with ultrasound-induced destruction of microbubbles administered as a constant venous infusion. Circulation 1998;97:473-483 (Pubitemid 28090220)
15. Barber PR, Vojnovic B, Ameer-Beg SM, Hodgkiss RJ, Tozer GM, Wilson J. Semi-automated software for the three-dimensional delineation of complex vascular networks. J Microsc 2003;211:54-62. (Pubitemid 41709852)
16. Norrby K. Microvascular density in terms of number and length of microvessel segments per unit tissue volume in mammalian angiogenesis. Microvasc Res 1998;55:43-53. (Pubitemid 28368412)
17. Gupta AK, Li B, Cerniglia GJ, Ahmed MS, Hahn SM, Maity A. The HIV protease inhibitor nelfinavir downregulates Akt phosphorylation by inhibiting proteasomal activity and inducing the unfolded protein response. Neoplasia (New York) 2007;9:271-278 (Pubitemid 46608294)
18. Ren W, Korchin B, Zhu QS, et al. Epidermal growth factor receptor blockade in combination with conventional chemotherapy inhibits soft tissue sarcoma cell growth in vitro and in vivo . Clin Cancer Res 2008;14:2785-2795
19. Janes PW, Daly RJ, deFazio A, Sutherland RL. Activation of the Ras signalling pathway in human breast cancer cells overexpressing erbB-2. Oncogene 1994;9:3601-3608
20. Andrechek ER, Muller WJ. Tyrosine kinase signalling in breast cancer: tyrosine kinase-mediated signal transduction in transgenic mouse models of human breast cancer. Breast Cancer Res 2000;2:211-216
21. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005;307:58-62.
22. Chaisuparat R, Hu J, Jham BC, Knight ZA, Shokat KM, Montaner S. Dual inhibition of PI3Ka and mTOR as an alternative treatment for Kaposi's sarcoma. Cancer Res 2008;68:8361-8368
23. Chen JS, Zhou LJ, Entin-Meer M, et al. Characterization of structurally distinct, isoform-selective phosphoinositide 3′-kinase inhibitors in combination with radiation in the treatment of glioblastoma. Mol Cancer Ther 2008;7:841-850 (Pubitemid 351551037)
24. Fan QW, Knight ZA, Goldenberg DD, et al. A dual PI3K/mTOR inhibitor reveals emergent efficacy in glioma. Cancer Cell 2006;9:341-349
25. Lobell RB, Liu D, Buser CA, et al. Preclinical and clinical pharmacodynamic assessment of L-778,123, a dual inhibitor of farnesyl:protein transferase and geranylgeranyl:protein transferase type-I. Mol Cancer Ther 2002;1:747-758
26. Cohen-Jonathan E, Muschel RJ, Gillies McKenna W, et al. Farnesyltransferase inhibitors potentiate the antitumor effect of radiation on a human tumor xenograft expressing activated HRAS. Radiat Res 2000;154:125-132 (Pubitemid 30612910)
27. Raynaud FI, Eccles S, Clarke PA, et al. Pharmacologic characterization of a potent inhibitor of class I phosphatidylinositide 3-kinases. Cancer Res 2007;67:5840-5850 (Pubitemid 46985018)
28. Hamel FG, Fawcett J, Tsui BT, Bennett RG, Duckworth WC. Effect of nelfinavir on insulin metabolism, proteasome activity and protein degradation in HepG2 cells. Diabetes Obes Metab 2006;8:661-668 (Pubitemid 44515563)
29. Piccinini M, Rinaudo MT, Anselmino A, et al. The HIV protease inhibitors nelfinavir and saquinavir, but not a variety of HIV reverse transcriptase inhibitors, adversely affect human proteasome function. Antiviral Ther 2005;10:215-223 (Pubitemid 41151027)
30. Gills JJ, Lopiccolo J, Tsurutani J, et al. Nelfinavir, A lead HIV protease inhibitor, is a broad-spectrum, anticancer agent that induces endoplasmic reticulum stress, autophagy, and apoptosis in vitro and in vivo . Clin Cancer Res 2007;13:5183-5194 (Pubitemid 47502088)
31. Pore N, Gupta AK, Cerniglia GJ, Maity A. HIV protease inhibitors decrease VEGF/HIF-1a expression and angiogenesis in glioblastoma cells. Neoplasia (New York) 2006;8:889-895 (Pubitemid 44706238)
32. Hirsch FR, Varella-Garcia M, Bunn PA, Jr., et al. Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis [see comment]. J Clin Oncol 2003;21:3798-3807 (Pubitemid 46606235)
33. Kalyankrishna S, Grandis JR. Epidermal growth factor receptor biology in head and neck cancer. J Clin Oncol 2006;24:2666-2672 (Pubitemid 46622088)
34. Hirata A, Ogawa S, Kometani T, et al. ZD1839 (Iressa) induces antiangiogenic effects through inhibition of epidermal growth factor receptor tyrosine kinase. Cancer Res 2002;62:2554-2560 (Pubitemid 34462734)
35. Mazzone M, Dettori D, Leite de Oliveira R, et al. Heterozygous deficiency of PHD2 restores tumor oxygenation and inhibits metastasis via endothelial normalization. Cell 2009;136:839-851
36. Gupta AK, Cerniglia GJ, Mick R, McKenna WG, Muschel RJ. HIV protease inhibitors block Akt signaling and radiosensitize tumor cells both in vitro and in vivo. Cancer Res 2005;65:8256-8265 (Pubitemid 41330590)
37. Milas L, Mason K, Hunter N, et al. In vivo enhancement of tumor radioresponse by C225 antiepidermal growth factor receptor antibody. Clin Cancer Res 2000;6:701-708
38. Brunner TB, Cengel KA, Hahn SM, et al. Pancreatic cancer cell radiation survival and prenyltransferase inhibition: the role of K-Ras. Cancer Res 2005;65:8433-8441
39. Cengel KA, Voong KR, Chandrasekaran S, et al. Oncogenic K-Ras signals through epidermal growth factor receptor and wild-type H-Ras to promote radiation survival in pancreatic and colorectal carcinoma cells. Neoplasia (New York) 2007;9:341-348 (Pubitemid 46608301)
40. Prevo R, Deutsch E, Sampson O, et al. Class I PI3K inhibition by the pyridinylfuranopyrimidine inhibitor PI- 103 enhances tumor radiosensitivity. Cancer Res 2008; 68:5915-5923